A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.

Kong, Li Ren; Mohamed Salleh, Nur Afiqah Binte; Ong, Richard Weijie; Tan, Tuan Zea; Syn, Nicholas L; Goh, Robby Miguel; Fhu, Chee Wai; Tan, Daniel S W; Iyer, N Gopalakrishna; Kannan, Srinivasaraghavan; Verma, Chandra S; Lim, Yaw Chyn; Soo, Ross; Ho, Jingshan; Huang, Yiqing; Lim, Joline S J; Yan, Benedict Junrong; Nga, Min En; Lim, Seng Gee; Koeffler, H Phillip; Lee, Soo Chin; Kappei, Dennis; Hung, Huynh The; Goh, Boon Cher

Kong, Li Ren; Mohamed Salleh, Nur Afiqah Binte; Ong, Richard Weijie; Tan, Tuan Zea; Syn, Nicholas L; Goh, Robby Miguel; Fhu, Chee Wai; Tan, Daniel S W; Iyer, N Gopalakrishna; Kannan, Srinivasaraghavan; Verma, Chandra S; Lim, Yaw Chyn; Soo, Ross; Ho, Jingshan; Huang, Yiqing; Lim, Joline S J; Yan, Benedict Junrong; Nga, Min En; Lim, Seng Gee; Koeffler, H Phillip; Lee, Soo Chin; Kappei, Dennis; Hung, Huynh The; Goh, Boon Cher.

Afiliación

Kong LR; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore. csiklr@nus.edu.sg.
Mohamed Salleh NAB; Medical Research Council Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK. csiklr@nus.edu.sg.
Ong RW; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
Tan TZ; Laboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Syn NL; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
Goh RM; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
Fhu CW; Department of Hematology-Oncology, National University Cancer Institute, Singapore, 119074, Singapore.
Tan DSW; Department of Hematology-Oncology, National University Cancer Institute, Singapore, 119074, Singapore.
Iyer NG; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
Kannan S; Cancer Therapeutics Research Laboratory, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Verma CS; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Lim YC; Genome Institute of Singapore, Agency for Science, Technology & Research (A*STAR), Singapore, 138672, Singapore.
Soo R; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
Ho J; Office of Clinical Sciences, Duke-NUS Medical School, Singapore, 169857, Singapore.
Huang Y; Division of Surgical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Lim JSJ; Bioinformatics Institute, Agency for Science, Technology, and Research (A*STAR), Singapore, 138671, Singapore.
Yan BJ; Bioinformatics Institute, Agency for Science, Technology, and Research (A*STAR), Singapore, 138671, Singapore.
Nga ME; Department of Biological Sciences, National University of Singapore, Singapore, 119228, Singapore.
Lim SG; School of Biological Sciences, Nanyang Technological University, Singapore, 639798, Singapore.
Koeffler HP; Department of Pathology, National University Health System, Singapore, 119074, Singapore.
Lee SC; Department of Hematology-Oncology, National University Cancer Institute, Singapore, 119074, Singapore.
Kappei D; Department of Hematology-Oncology, National University Cancer Institute, Singapore, 119074, Singapore.
Hung HT; Department of Hematology-Oncology, National University Cancer Institute, Singapore, 119074, Singapore.
Goh BC; Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.

Nat Commun ; 11(1): 1556, 2020 03 25.

Article en En | MEDLINE | ID: mdl-32214092

Asunto(s)

Carcinoma de Células Escamosas/genética; Carcinoma de Células Escamosas/patología; Proteínas Proto-Oncogénicas c-met/genética; Proteínas Proto-Oncogénicas c-met/metabolismo; Receptor ErbB-2/metabolismo; Animales; Antineoplásicos/farmacología; Antineoplásicos/uso terapéutico; Carcinoma de Células Escamosas/tratamiento farmacológico; Carcinoma de Células Escamosas/mortalidad; Línea Celular Tumoral; Neoplasias de Cabeza y Cuello/tratamiento farmacológico; Neoplasias de Cabeza y Cuello/genética; Neoplasias de Cabeza y Cuello/mortalidad; Neoplasias de Cabeza y Cuello/patología; Humanos; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/mortalidad; Neoplasias Pulmonares/patología; Ratones; Mutación; Fenotipo; Fosforilación/efectos de los fármacos; Polimorfismo Genético; Pronóstico; Unión Proteica; Dominios y Motivos de Interacción de Proteínas; Inhibidores de Proteínas Quinasas/farmacología; Inhibidores de Proteínas Quinasas/uso terapéutico; Proteínas Proto-Oncogénicas c-met/química; Receptor ErbB-2/antagonistas & inhibidores; Transducción de Señal/efectos de los fármacos; Ensayos Antitumor por Modelo de Xenoinjerto

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Receptor ErbB-2 / Proteínas Proto-Oncogénicas c-met Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2020 Tipo del documento: Article País de afiliación: Singapur

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google